Physician profile
David Z Chee
NPI 1306846373
$2,023.74
in general payments reported to CMS, 2019-2025
11 companies · $71.90 in 2025
The $71.90 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $552 · 2020: $262 · 2021: $402 · 2022: $458 · 2023: $130 · 2024: $148 · 2025: $71.90.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $326 · Education: $23.34.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $326.38 |
| Education | $23.34 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $518.71 | 2019-2024 | Jardiance |
| Glaxosmithkline, LLC. | $479.24 | 2019-2023 | |
| Astrazeneca Pharmaceuticals LP | $365.31 | 2021-2022 | |
| Teva Pharmaceuticals USA, INC. | $229.61 | 2019-2020 | |
| Amgen INC. | $125.00 | 2021 | |
| Abbvie INC. | $109.20 | 2022 | |
| Pfizer INC. | $88.76 | 2019 | |
| Insmed, INC. | $50.46 | 2025 | Arikayce |
| Gilead Sciences, INC. | $21.44 | 2025 | |
| Dexcom, INC. | $19.39 | 2023 | Dexcom G6 Transmitter |
| Medtronic, INC. | $16.62 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Chee listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.